NCT01849003View on ClinicalTrials.gov

Study of the Effect of GS-6615 in Subjects With LQT-3

PHASE1CompletedINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions

Long QT Syndrome

Interventions

DRUG

GS-6615

GS-6615 tablet(s) administered orally

Trial Locations (1)

14620

University of Rochester Medical Center/Strong Memorial Hospital, Rochester

Sponsors

Lead Sponsor

Gilead Sciences

All Listed Sponsors

lead

Gilead Sciences

INDUSTRY